Pexastimogene Devacirepvec (Pexa-Vec)
JX594-REN026
Phase 2 mab active
Quick answer
Pexastimogene Devacirepvec (Pexa-Vec) for Renal Cell Carcinoma is a Phase 2 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Renal Cell Carcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active